

# INDEX

## SUBPART 58-2

### BLOOD BANKS

November 7, 2007

#### A

- A Cells in ABO grouping 58-2.3(f), 58-2.17(a)
- ABO compatibility 58-2.7
  - red cells components 58-2.9(c), 58-2.7, 58-2.17, 58-2.20(d)
- ABO group 58-2.7
  - allogeneic blood 58-2.3(f)
  - autogeneic blood 58-2.3(f)
  - confirmation of donor units 58-2.17(a)
  - emergency release 58-2.17(c)
  - label 58-2.6(d)
  - neonates 58-2.20(d)
  - recipient blood 58-2.17(a)
  - records of test results 58-2.11(a), 58-2.12(a), 58-2.18(b)
  - selection of components 58-2.9(c)
  - required tests 58-2.3(f)
- ABO incompatibility 58-2.7
  - crossmatching to detect 58-2.17(c),(e)
- Accidents 58-2.3(h), 58-2.8(b), 58-2.16(a), 58-2.27(h)
- ACD anticoagulant 58-2.6(d)(2)
- Adverse reactions
  - blood donors 58-2.3(h)
  - cytapheresis donors 58-2.15(c)
  - serial plasmapheresis donors 58-2.14(e)
  - transfusion recipients 58-2.16(a)
  - reinfusion 58-2.27(h)
  - standard operating procedures 58-2.8
- Age
  - allogeneic donors 58-2.2(c)
  - autogeneic donors 58-2.2(e)
- AIDS
  - donor educational materials 58-2.2(d)
  - donor screening 58-2.2(b)
  - See also anti-HIV-1, anti-HIV-2, HIV*
- Alarms
  - blood storage devices 58-2.6(g),(h),(j),
  - blood warmers 58-2.8(c), 58-2.16(j), 58-2.25(b)
- Albumin
  - recordkeeping 58-2.19
- Aliquots
  - compatibility testing 58-2.9(i), 58-2.17(f)
- Allogeneic blood
  - definition 58-2.1(p)
  - donation criteria 58-2.2(b),(c),(d)
  - frequency of collection 58-2.4(c)
  - labeling 58-2.6(d)
  - minimum hemoglobin/hematocrit 58-2.2(c)
  - records of issuance 58-2.12
  - specimen for testing 58-2.6(e)
  - storage 58-2.6(g)
  - testing 58-2.3(a),(f),(g), 58-2.9(b)
  - volume 58-2.4(b)
- Anti-D
  - allogeneic donor testing 58-2.3(f)
  - autogeneic donor testing 58-2.3(f)
  - recipient testing 58-2.17(a)
- Anti-HBc
  - biohazard labeling 58-2.6(d)(3)(ii)(f)
  - allogeneic donor testing 58-2.3(a), 58-2.9(b)
  - autogeneic donor testing 58-2.3(a), 58-2.9(b)
  - cytapheresis testing 58-2.3(a),(d),(e), 58-2.9(b)
  - labeling 58-2.6(d)
  - serial plasmapheresis testing 58-2.14(f)
  - required test for 58-2.3(a)
  - test controls 58-2.3(a)
- Anti-HCV
  - biohazard labeling 58-2.6(d)(3)(ii)(f)
  - allogeneic donor testing 58-2.3(a), 58-2.9(b)
  - autogeneic donor testing 58-2.3(a), 58-2.9(b)
  - cytapheresis testing 58-2.3(a),(d),(e)
  - labeling 58-2.6(d)
  - serial plasmapheresis testing 58-2.14(f)
  - test controls 58-2.3(a)
- Anti-HIV-1
  - biohazard labeling 58-2.6(d)(3)(ii)(f)
  - allogeneic donor testing 58-2.3(a), 58-2.9(b)
  - autogeneic donor testing 58-2.3(a), 58-2.9(b)
  - controls 58-2.3(a)
  - cytapheresis testing 58-2.3(a),(d),(e)
  - incomplete test results 58-2.3(b)
  - notification of test results 58-2.23
  - serial plasmapheresis testing 58-2.14(f)
  - reporting of test results 58-2.3(b)
  - required testing for 58-2.3(a)
  - weak reactive control 58-2.3(b)
  - verification of test results 58-2.3(b)
- Anti-HIV-2
  - biohazard labeling 58-2.6(d)(3)(ii)(f)
  - allogeneic donor testing 58-2.3(a), 58-2.9(b)
  - autogeneic donor testing 58-2.3(a), 58-2.9(b)

Anti-HIV-2 (cont)  
 cytapheeresis testing 58-2.3(a),(d),(e)  
 notification of test results 58-2.23  
 serial plasmapheresis testing 58-2.14(f)  
 reporting of test results 58-2.3(b)  
 required testing for 58-2.3(a)  
 test controls 58-2.3(a)

Anti-HTLV-I/II  
 biohazard labeling 58-2.6(d)(3)(ii)(f)  
 allogeneic donor testing 58-2.3(a),  
 58-2.9(b)  
 autogeneic donor testing 58-2.3(a),  
 58-2.9(b)  
 controls 58-2.3(a)  
 cytapheeresis testing 58-2.3(a),(d),(e)  
 serial plasmapheresis testing 58-2.14(f)  
 required testing 58-2.3(a)

Antibodies  
 testing allogeneic donors 58-2.3(g)  
 testing recipients 58-2.17(b)  
 unexpected – *See unexpected antibodies*

Anticoagulants 58-2.6(b),(d)

Antiglobulin testing 58-2.7  
 unexpected antibodies 58-2.17(b)  
 crossmatching 58-2.7, 58-2.17(c)

Apheresis – *See cytapheeresis, serial  
 plasmapheresis*

Aspirin  
 ingestion by cytapheeresis donors  
 58-2.15(c)

At-risk behavior of donors 58-2.2(b),(c),(d)

Autogeneic blood  
 biohazard labeling 58-2.6(d)(3)(ii)(f)  
 definition 58-2.1(q)  
 donation criteria 58-2.2(e),(f)  
 frequency of collection 58-2.2(e)  
 labeling 58-2.6(d)  
 minimum hemoglobin/hematocrit 58-2.2(e)  
 positive test result - release of 58-2.9(b)  
 procedures to encourage the use  
 58-2.16(i)  
 records of issuance 58-2.12  
 required tests 58-2.3(a)  
 shipping 58-2.6(m)  
 specimens for testing 58-2.6(e)  
 storage 58-2.6(g)  
 testing 58-2.3(a),(f)  
 volume 58-2.4(b)

Autologous blood – *See autogeneic blood*

## B

B Cells in ABO grouping 58-2.3(f), 58-2.17(a),  
 58-2.20(d)

Blood bank  
 definition 58-2.1(a)

Blood collection 58-2.4, 58-2.6(f)

Blood collection systems  
 minimum requirements 58-2.6(d)

Blood components  
 administration 58-2.16(d)  
 definition 58-2.1(d)  
 expiration 58-2.6(f),(h),(j)  
 issuance of 58-2.6(f) through 58-2.6(l),  
 58-2.9  
 labeling 58-2.6(d)  
 preparation 58-2.6(f)  
 records of issuance 58-2.12  
 storage 58-2.6(d)(2), 58-2.6(f) through (j),  
 (l) and (m)  
 transportation 58-2.6(g),(m), 58-2.9(a)

Blood derivatives  
 administration 58-2.16(d)  
 definition 58-2.1(e)  
 issuance 58-2.9  
 records of issuance 58-2.12

Blood donation center 58-2.13  
 definition 58-2.1(b)

Blood pressure  
 donors 58-2.2(c)

Blood products  
 definition 58-2.1(f)

Blood recovery 58-2.25

Blood samples – *See samples*

Blood Services Activity Report 58-2.10(b),  
 58-2.11(b)

Blood warming 58-2.16(j)  
 standard operating procedure 58-2.8(c),  
 58-2.16(j)  
 intraoperative and postoperative  
 58-2.25(b)

## C

Care of  
 blood donors 58-2.2  
 cytapheeresis donors 58-2.15(c)  
 serial plasmapheresis donors 58-2.14(e)

Centrifuges  
 calibration of 58-2.7(e)

Circular of information 58-2.6(d),(n)

Coagulation factor concentrates  
 investigation of reactions 58-2.12(c)  
 records 58-2.12(b)

Collection of blood components by apheresis  
 58-2.4, 58-2.6, 58-2.13 (d)  
 care of donor 58-2.15(c)  
 consent 58-2.15(b)

Collection of blood components by apheresis (cont)

- definition 58-2.1(i)
- direction 58-2.15(c)
- donor selection 58-2.15(a),(c)
- double red cell pheresis 58-2.15(d)
- issuance 58-2.9(b)
- multiple patient-dedicated 58-2.3(e)
- physician availability 58-2.15(c)
- procedure 58-2.15(f)
- qualifications and care of donor 58-2.15(c)
- red cell, double pheresis 58-2.15(d)
- red cell loss 58-2.15(d)
- release 58-2.9(b)
- required tests 58-2.3
- return of rbc 58-2.15
- records 58-2.15(g)
- supervision 58-2.15(c)
- testing 58-2.3(a),(d),(e), 58-2.9(b)
- training 58-2.15(c)
- volume and frequency 58-2.15(d)

Compatibility testing

- blood and blood components 58-2.7(a),  
58-2.17(a),(c)
- neonates 58-2.20(d)
- emergency issue 58-2.8(c), 58-2.9(c),  
58-2.17(c), 58-2.18(h)
- massive transfusion 58-2.17(c)
- procedure 58-2.17(e)
- recordkeeping 58-2.12(a)
- reservation of blood 58-2.16(c)
- samples 58-2.6(e), 58-2.17(d)

Computer system

- validation 58-2.17(a)

Confidential unit exclusion 58-2.2(d)

Confidentiality of records 58-2.10

Confirmation

- patient identity prior to reinfusion  
58-2.27(g)
- patient identity prior to transfusion  
58-2.16(f)

Consent

- allogeneic 58-2.4(a)
- autogeneic 58-2.2(a), 58-2.4(a)
- cytapheresis 58-2.15(b)
- exceptions 58-2.26(a)
- HIV testing 58-2.4(a)
- minors 58-2.2(c)
- out of hospital transfusion 58-2.21(c)
- serial plasmapheresis 58-2.14(c),(j)
- release of information 58-2.10

Containers

- blood collection 58-2.6(a)
- cytapheresis 58-2.15(f)
- infectious waste 58-2.21(f)
- serial plasmapheresis 58-2.14(h),(i)
- reinfusion 58-2.27(e)

Contamination

- protection against 58-2.2(b), 58-2.6(d),(f)
- visual inspection 58-2.9(d)

Coolant

- suitable 58-2.9(j)

CPD anticoagulant 58-2.6(d)(2)

CPDA-1

- anticoagulant 58-2.6(d)(2)
- crossmatching 58-2.6(e)

Crossmatching – *See compatibility testing*

Cryoprecipitate

- expiration 58-2.6(f),(h)
- Factor VIII replacement 58-2.6(f)
- storage 58-2.6(h)
- thawing 58-2.6(f), 58-2.6(l)

Cytapheresis – *See collection of blood components by apheresis*

Cytomegalovirus (CMV)

- CMV negative products 58-2.16(a)

**D**

D antigen

- donor testing 58-2.3(f)
- recipient testing 58-2.17(a)

Deferral records 58-2.9(l), 58-2.11(h)

Definitions 58-2.1

Deglycerolized red blood cells

- expiration 58-2.6(f),(j)
- storage 58-2.6(g)

Department

- definition 58-2.1(t)

Derivatives

- definition 58-2.1(e)
- recordkeeping 58-2.12(b),(c), 58-2.19

Directed donation – *See allogeneic blood*

- definition 58-2.1(r)

Director of transfusion services

- responsibilities 58-2.16(a)

Disease transmission

- donor notification 58-2.23
- screening to prevent 58-2.2
- testing to prevent 58-2.3

Disposal

- expired units 58-2.24
- unacceptable units 58-2.3(b)
- untransfused units 58-2.24

Disposition of

- blood for transfusion 58-2.6(m)
- recovered blood 58-2.6(m)

Disposition records

- collection 58-2.11
- transfusion 58-2.12, 58-2.18, 58-2.19

Donation interval

- allogeneic 58-2.4(c)
- Donation interval (cont)
  - autogeneic 58-2.2(e)
  - cytapheresis 58-2.15(d)
- Donation quantity 58-2.4(b)
- Donor definition 58-2.1(c)
- Donor testing 58-2.3
- Donor deferral 58-2.9(l), 58-2.11(h)
- Donors
  - allogeneic – *See allogeneic blood*
  - autogeneic – *See autogeneic blood*
  - cytapheresis 58-2.15
  - deferral records 58-2.9(l), 58-2.11(h)
  - directed – *See allogeneic blood*
  - educational materials for 58-2.2(d)(1)
  - serial plasmapheresis 58-2.14
  - qualifications of 58-2.2, 58-2.14(d)
    - cytapheresis 58-2.15(d)
    - serial plasmapheresis 58-2.14(e)
  - records of collection 58-2.11
  - selection criteria 58-2.2
- Drugs
  - addition to blood 58-2.16(e)
  - cytapheresis donors 58-2.15(b),(c)
  - serial plasmapheresis donors 58-2.14(c)
  - use of illegal 58-2.2(c)

## E

- Educational material for donors 58-2.2(d)(1)
- Emergency issue of blood 58-2.3(a), 58-2.8(c),
  - 58-2.9(a),(b),(g),
  - 58-2.17(c), 58-2.18(h)
- exceptions 58-2.26(b)
- Equipment
  - blood collection 58-2.6(b),(d)
  - blood storage 58-2.6(g) through 58-2.6(j)
  - blood irradiation 58-2.6(k)
  - thawing frozen products 58-2.6(l)
  - records of testing 58-2.7(d)
  - sterility 58-2.5
- Errors
  - collection 58-2.3(h)
  - reinfusion 58-2.27(h)
  - transfusion 58-2.16(a)
  - procedure manual 58-2.8(b)
- Exceptions 58-2.26
- Expiration date
  - cryoprecipitate 58-2.6(f),(h)
  - deglycerolized red cells 58-2.6(f)
  - fresh frozen plasma 58-2.6(f),(h)
  - frozen red cells 58-2.6(j)
  - labeling 58-2.6(d)
  - open system 58-2.6(f)

- red blood cells 58-2.6(g)

- Expired Units
  - disposal 58-2.24
  - storage 58-2.24

## F

- FDA – *See Food and Drug Administration*
- FFP – *See fresh frozen plasma*
- Filters for transfusion 58-2.16(d)
- Food and Drug Administration
  - approved additive solutions 58-2.6(d)
  - compliance 58-2.7(a)
  - criteria for containers, anticoagulants and reagents 58-2.6(d)
  - definition 58-2.1(k)
- Freezers
  - alarms 58-2.6(h),(j)
  - cryoprecipitate storage 58-2.6(h)
  - frozen red blood cell storage 58-2.6(j)
  - plasma storage 58-2.6(h)
  - temperature recording 58-2.6(h),(j)
- Frequency of donation
  - allogeneic 58-2.4(c)
  - autogeneic 58-2.2(e)
  - cytapheresis 58-2.15(d),(e)
  - serial plasmapheresis 58-2.14(g)
- Fresh frozen plasma
  - expiration 58-2.6(f),(h)
  - relabeling prohibited 58-2.6(h)
  - storage 58-2.6(f), 58-2.6(h)
  - thawing 58-2.6(f), 58-2.6(l)
- Frozen red blood cells
  - expiration 58-2.6(f),(j)
  - refreezing 58-2.6(f)
  - storage 58-2.6(j)
  - thawing 58-2.6(f),(j),(l)

## G

- Granulocytes
  - blood component 58-2.1(d)
  - cytapheresis 58-2.15
- Growth hormone
  - donors 58-2.2(c)(11)

## H

- HBsAg – *See hepatitis*
- HCV – *See hepatitis*
- Hemapheresis 58-2.1(i), 58-2.14(b)
  - See also collection of blood components by apheresis 58-2.15, and*

*serial plasmapheresis 58-2.14*

Hematocrit  
allogeneic donors 58-2.2(c)  
autogeneic donors 58-2.2(e),(f)  
recordkeeping 58-2.11(e)

Hemodilution – *See isovolemic hemodilution*

Hemoglobin  
allogeneic donors 58-2.2(c)  
autogeneic donors 58-2.2(e),(f)  
recordkeeping 58-2.11(e)

Heparin  
anticoagulant 58-2.6(d)(2)

Hepatitis  
biohazard labeling 58-2.6(d)(3)(ii)(f)  
controls 58-2.3(a)  
donor history 58-2.2(b)  
labeling 58-2.6(d)  
nucleic acid testing for HCV 58-2.3(a)  
required testing 58-2.3(a)  
testing allogeneic donors 58-2.3(a),  
58-2.9(b)  
testing autogeneic donors 58-2.3(a),  
58-2.9(b)  
testing cytapheresis donors  
58-2.3(a),(d),(e)  
testing serial plasmapheresis 58-2.14(f)

HIV – *See also anti-HIV-1 and anti-HIV-2*  
donor screening 58-2.2(b)  
education 58-2.2(d)(1)  
labeling 58-2.6(d)(3)  
nucleic acid testing for HIV 58-2.3(a)  
testing results 58-2.23  
testing for 58-2.3(a)

Holding facility 58-2.22  
definition 58-2.1(m)

Homologous – *See allogeneic blood*

HTLV-I/II – *See anti-HTLV-I/II*

Human growth factor  
donor deferral 58-2.2(c)

**I**

Identification  
blood prior to transfusion 58-2.16(f)  
recipient before transfusion 58-2.16(f)  
red cells from manual pheresis prior to  
reinfusion 58-2.14(h)  
samples for reinfusion 58-2.27(g)

Identification number for donor units 58-2.6(d)

Illegal injectable drug use in donors 58-2.2(c)

Immunohematology testing 58-2.7

Incident reporting  
collection 58-2.3(h)  
reinfusion 58-2.27(h)

transfusion 58-2.16(a)  
procedure manual 58-2.8(b)

Informed consent – *See consent*

Inspection of blood products  
prior to issuance 58-2.8(c), 58-2.9(d)

Institution  
definition 58-2.1(o)

Intraoperative blood recovery  
definition 58-2.1(j)  
identification procedures 58-2.25(d)  
methods 58-2.25(b)  
protocol for 58-2.25(c)  
recordkeeping 58-2.25(i)  
storage 58-2.25(e)  
transfusion 58-2.25(a),(e)  
untested units 58-2.25(g)

Irradiation  
labeling of irradiated products 58-2.6(k)  
maintenance 58-2.6(k)  
protocol 58-2.6(k)  
responsibility 58-2.6(k)

Isovolemic hemodilution – *See normovolemic  
hemodilution*

Issuance of blood, components, derivatives  
58-2.6, 58-2.9  
emergency 58-2.18(h)  
inspection prior to transfusion 58-2.9(d)  
NYS-approved sites 58-26(m)  
order for 58-2.9(c)  
records 58-2.9(h), 58-2.12  
records of issuance 58-2.12  
reissue 58-2.9(j)  
responsibility 58-2.16(a)(3)  
retention of blood samples 58-2.9(i)  
return unit to blood bank 58-2.9(h),(j)  
sequence of issuance 58-2.9(k)  
transportation container 58-2.9(a)  
urgent requirement 58-2.9(g)

**L**

Labeling  
ABO group 58-2.6(d)  
allogeneic 58-2.6(d)  
at collection 58-2.6(d)  
autogeneic 58-2.6(d),(g)  
biohazard 58-2.6(d)(3)(ii)(f)  
blood or blood components 58-2.9(k)  
donor identification number 58-2.6(d)  
pilot blood specimen 58-2.6(d)  
pre-transfusion specimens 58-2.7(a)  
Rh group 58-2.6(d)  
relabeling of components 58-2.6(h)  
shipping container 58-2.9(a)  
test results 58-2.6(d)

- testing not completed 58-2.9(b)
- unacceptable test results 58-2.3(a)
- Laboratory permit 58-2.6(a)
- Licensed practical nurses 58-2.16(d)
- Limited transfusion service
  - agreement 58-2.21(b)
  - availability of MD 58-2.21(e)
  - coverage, 24-hour-a-day 58-2.16(h)
  - definition 58-2.1(l)
  - medical supervision 58-2.21(d)
  - out-of-hospital transfusions 58-2.21(c)
  - patient requirements 58-2.21(c)
  - recordkeeping 58-2.12

## M

- Malaria
  - Donor history 58-2.2(b)
- Manufacturer's instructions
  - compliance with 58-2.7(c)
- Massive transfusion 58-2.17(c)
- Medical director
  - allogeneic donation 58-2.2(a), 58-2.6(a)
  - autogeneic donation 58-2.2(e), 58-2.6(a)
  - definition 58-2.1(s)
  - direction 58-2.6(a)
- Medical services
  - care of donor 58-2.6(a)
- Medications added to blood 58-2.16(e)
- Microscopes
  - maintenance 58-2.7(d)
  - use of 58-2.7(d)
- Minors
  - blood donation 58-2.2(c)

## N

- Neonatal transfusion 58-2.20, 58-2.17(d)
- Normovolemic hemodilution
  - definition 58-2.1(j),(v)
  - identification procedures 58-2.25(d)
  - methods 58-2.25(b)
  - protocol 58-2.25(c)
  - recordkeeping 58-2.25(i)
  - storage 58-2.25(f)
  - transfusion 58-2.25(a)
  - untested units 58-2.25(g)
- Notification
  - HIV-1 and HIV-2 test results 58-2.23

## O

- Open system 58-2.6(f)
- Ordering blood components 58-2.9(c)
- Ordering blood derivatives 58-2.9(c)
- Out-of-hospital transfusions – *See limited transfusion services*

## P

- Permits
  - blood collection 58-2.6(a)
  - for required testing 58-2.3(a)
- Pheresis – *See cytopheresis, serial plasmapheresis*
- Phlebotomy
  - apparatus 58-2.6(b)
  - records of collections 58-2.11
  - phlebotomy sites 58-2.6(c)
- Physician
  - approval for autogeneic donation 58-2.2(a),(e)
  - order for transfusion 58-2.9(c)
  - out-of-hospital transfusion 58-2.21(d),(e)
  - See also medical director*
- Plasma – *See fresh frozen plasma fractionation* 58-2.3(c), 58-2.9(b)
- Plasma derivatives
  - definition 58-2.1(e)
  - recordkeeping 58-2.19
- Plasmapheresis – *See serial plasmapheresis*
- Platelets
  - donated by infant's mother 58-2.3(d)
  - storage 58-2.6(g),(i)
- Pooling blood components 58-2.9(f)
- Postoperative recovery
  - definition 58-2.1(j)
  - identification procedures 58-2.25(d)
  - methods 58-2.25(b)
  - protocol 58-2.25(c)
- Postoperative recovery
  - recordkeeping 58-2.25(i)
  - storage 58-2.25(e)
  - transfusion 58-2.25(a),(h)
  - untested units 58-2.25(e)
- Procedure manual 58-2.8
- Pulse
  - donors 58-2.2(c)

## Q

- Quality control
  - recordkeeping 58-2.7(d)
  - testing 58-2.7(b),(c),(d)
- Quantity
  - allogeneic donation 58-2.4(b)
  - autogeneic donation 58-2.4(b)

## Quarantine

- unacceptable blood 58-2.3(a)
- untested blood 58-2.3(a)

## R

### Reactions – *See also incident reporting*

- conclusions signed by director 58-2.12(a)
- records to be kept by blood bank 58-2.12, 58-2.18, 58-2.19
- records to be kept on patient chart 58-2.18, 58-2.19

### Reagents

- ABO grouping 58-2.3(f), 58-2.17(a)
- antibody detection 58-2.3(g), 58-2.17(b)
- manufacturer's instructions 58-2.7(b)
- records 58-2.7(d)
- Rh grouping 58-2.3(f), 58-2.17(a)
- storage 58-2.6(g), 58-2.7(b)

### Recipient

- blood sample retention 58-2.17(f)
- blood testing 58-2.7, 58-2.17
- identification of prior to transfusion 58-2.16(f)

### Records

- confidentiality 58-2.10
- deferral 58-2.9(l), 58-2.11(h)
- coagulation factor concentrates 58-2.12(b), 58-2.12(c)
- collection 58-2.11
- cytapheresis 58-2.15(g)
- infusions 58-2.19
- issuance for transfusion 58-2.12
- plasma derivative infusion 58-2.19
- required 58-2.10
- retention of 58-2.10
- serial plasmapheresis 58-2.14(j)
- temperature 58-2.6(g),(h),(j), and (l)
- transfusions 58-2.12, 58-2.18

### Red blood cells

- deglycerolized 58-2.6(f),(g),(j)
- double red cell pheresis 58-2.15(d)
- expiration 58-2.6
- frozen 58-2.6(j)
- storage of 58-2.6(g), 58-2.9(j)

### Refrigerators

- alarms 58-2.6(g)
- blood storage 58-2.6(g)
- temperature recording 58-2.6(g)

### Reinfusion 58-2.27

- definition 58-2.1(u)
- errors 58-2.27(h)
- labeling 58-2.27(c), 58-2.27(e)
- permit 58-2.27(f)
- positive identification prior to reinfusion 58-2.27(g)
- retention of records 58-2.27(i)

- review 58-2.27(b)
- storage 58-2.27(d)

### Reissue of blood 58-2.9(j)

### Respiratory diseases

- donors 58-2.2(b)

### Responsibility for

- blood collected by phlebotomy 58-2.6(m)
- blood intended for transfusion 58-2.6(m)
- limited transfusion 58-2.21(b)
- procedure manuals 58-2.8
- recovered blood 58-2.6(m)
- reinfusion 58-2.27
- required tests 58-2.3(f)
- testing 58-2.3(b), 58-2.7(b)
- transfusion committee 58-2.16
- transfusion services 58-2.16(a)

### Retention

- compatibility samples 58-2.17(f)
- blood issued for transfusion 58-2.9(i)
- records 58-2.10, 58-2.11(a)
- temperature records 58-2.6, 58-2.16(j)

### Rh group

- confirmation 58-2.17(a)
- labeling 58-2.6(d)
- allogeneic collections 58-2.3(f)
- autogeneic collections 58-2.3(f)
- neonates 58-2.20
- recipients 58-2.17(a)
- required tests 58-2.3(f)
- selecting blood for transfusion 58-2.9(c)
- testing 58-2.7, 58-2.17
- weak D 58-2.3(f)

## S

### Saline – *See sodium chloride*

### Samples

- blood issued for transfusion 58-2.9(i)
- donor testing 58-2.6(e)
- labeling pilot samples 58-2.6(d)(3)(i)
- pretransfusion 58-2.17(f)
- storage of 58-2.6(g)

### Seal

- closed system 58-2.6(d)
- open system 58-2.6(f)

### Selection criteria

- allogeneic donors 58-2.2
- autogeneic donors 58-2.2
- cytapheresis donors 58-2.15
- serial plasmapheresis donors 58-2.14

### Self-exclusion 58-2.2(d)

### Serial Plasmapheresis

- automated procedure 58-2.14(i)
- care of donor 58-2.14(e)
- consent 58-2.14(c)

- definition 58-2.1(g),(h)
- direction 58-2.14(b)
- donor selection 58-2.14(a),(d)
- Serial plasmapheresis (cont)
  - donor testing 58-2.14(f)
  - laboratory testing 58-2.14(f)
  - manual procedure 58-2.14(h)
  - physician availability 58-2.14(e)
  - records 58-2.14(j)
  - required tests 58-2.3, 58-2.7, 58-2.14(f), 58-2.17
  - return of red cells 58-2.14(g)
  - serial 58-2.14(e)
  - standards 58-2.14(a)
  - supervision 58-2.14(e)
  - training 58-2.14(e)
- Sexually transmitted diseases
  - donors 58-2.2(b)
- Skin
  - diseases in donors 58-2.2(b)
  - lesions in donors 58-2.2(b)
- Sodium chloride 0.9%
  - intraoperative blood recovery 58-2.25(e)
  - transfusion 58-2.16(e)
- SOPM 58-2.8
- Specimens
  - allogeneic donor testing 58-2.6(e)
  - autogeneic donor testing 58-2.6(e)
  - compatibility testing 58-2.6(e), 58-2.17(f) 58-2.7(a),(b),(d)
  - storage of 58-2.6(g)
- Standard operating procedures 58-2.8
- Sterile connecting device 58-2.6(f)
- Sterility of equipment 58-2.5, 58-2.6(b)
- Storage of blood – *See individual components*
- Supervision
  - cytapheresis 58-2.15(c)
  - serial plasmapheresis 58-2.14(e)
- Syphilis
  - allogeneic donor testing 58-2.3(a), 58-2.9(b)
  - autogeneic donor testing 58-2.3(a), 58-2.9(b)
  - biohazard labeling 58-2.6(d)(3)(ii)(f)
  - controls 58-2.3(a)
  - cytapheresis donor testing 58-2.3(a),(d),(e)
  - donor history 58-2.2(b)
  - labeling 58-2.6(d)
  - required laboratory test 58-2.3
  - serial plasmapheresis donor testing 58-2.9(b), 58-2.14(f)

## T

- Temperature, storage
  - blood in transit 58-2.6(g)
  - cryoprecipitate 58-2.6(h)
  - deglycerolized red cells 58-2.6(g)
  - fresh frozen plasma 58-2.6(f),(h)
  - frozen red cells 58-2.6(f),(j)
  - platelets 58-2.6(i)
  - records of 58-2.6
  - red cells 58-2.6(g), 58-2.9(j)
  - whole blood 58-2.6(g)
- Temperature for warming blood 58-2.16(j), 58-2.25(b)
- Temperature of donor 58-2.2(c)
- Testing
  - ABO group 58-2.3(f), 58-2.7(b), 58-2.17(a)
  - algorithms 58-2.3(b)
  - allogeneic blood 58-2.3, 58-2.9(b)
  - antibody screening 58-2.3(g), 58-2.7 (b), 58-2.17(b)
  - autogeneic blood 58-2.3
  - compatibility 58-2.7(a),(b), 58-2.17(c)
  - controls 58-2.3(a)
  - cytapheresis 58-2.3, 58-2.9(b)
  - immunohematology 58-2.7
  - neonatal 58-2.20
  - notification of donor HIV results 58-2.23
  - Rh group 58-2.3(f), 58-2.7, 58-2.17(a)
  - recipient blood 58-2.7, 58-2.17
  - records 58-2.10
  - reports 58-2.3(a) 58-2.3(b)
  - required laboratory tests 58-2.3, 58-2.7, 58-2.17
  - results 58-2.3(a), 58-2.3(b)
  - serial plasmapheresis donors 58-2.14
- Thawing
  - cryoprecipitate 58-2.6(f),(l)
  - fresh frozen plasma 58-2.6(f),(l)
  - frozen red cells 58-2.6(f),(l)
- Therapeutic procedures 58-2.2(g)
- Transfusion
  - availability of person administering the transfusion 58-2.16(f)
  - committee 58-2.16(b)
  - donor history 58-2.2(c)
  - identification of recipient and blood to be transfused 58-2.16(f)
  - limited transfusion 58-2.21
  - massive 58-2.17(c)
  - neonatal 58-2.20
  - outside health care setting 58-2.16(g)
  - qualifications of personnel 58-2.16(d)
  - reinfusion 58-2.27
  - required records 58-2.18
  - plasma derivatives 58-2.19
  - required standards for 58-2.16(a)

Transfusion committee 58-2.16(b) storage 58-2.6(g)  
composition of 58-2.16(b)  
procedures 58-2.16(b), 58-2.16(i)  
reservation of blood 58-2.16(c)

Transfusion complications November 7, 2007  
reporting 58-2.16(a)  
records 58-2.12(a),(c), 58-2.18(f),  
58-2.19(d)  
*See also errors*

Transfusion service  
definition 58-2.1(n)  
responsibility of director 58-2.16(a)

Transportation  
authorization 58-2.6(m)  
container 58-2.9(a)  
*See individual components*

Tuberculosis  
donor history 58-2.2(b)

## U

Unacceptable test results 58-2.3(a), 58-2.9(b)

Unexpected antibodies  
neonates 58-2.20  
samples 58-2.17(d)  
testing allogeneic blood 58-2.3(g)  
testing recipients 58-2.17(b)

Untested blood 58-2.9(b)

## V

Validation  
computer system 58-2.17(a)

Venipuncture  
preparation of site 58-2.6(c)

Viral hepatitis  
donor history 58-2.2(b)

Volume  
allogeneic blood collection 58-2.4(b)  
autogeneic blood collection 58-2.4(b)  
within 8-week period 58-2.4(c)

## W

Warming  
reinfusion 58-2.25(b)  
transfusion 58-2.16(j)

Weight  
donor 58-2.2(c)

Whole blood  
issuance 58-2.9(d)  
preparation of platelets 58-2.6(g)

